ELAVL1 and nervous system disorder: Alterations in RBP expression levels and function have been associated with neurological disorders (e.g. HNRNPA1 [45], MATR3 [46,47], TIA1 [48], and TARDBP [49] and brain tumour development (e.g. Musashi1 [8,50,51], SERBP1 [11], PTB [12] and HuR [17].